| Bioactivity | SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN-16 binds to the active site and forms a covalent bond with Cys145 of 3CLpro[1]. |
| Target | 2.124 μM (SARS-CoV-2 3CLpro) |
| Name | SARS-CoV-2 3CLpro-IN-16 |
| CAS | 352659-40-6 |
| Formula | C17H14N2OS |
| Molar Mass | 294.37 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ren P, et al. Discovery and Mechanism Study of SARS-CoV-2 3C-like Protease Inhibitors with a New Reactive Group. J Med Chem. 2023 Aug 18. |
SARS-CoV-2 3CLpro-IN-16
CAS: 352659-40-6 F: C17H14N2OS W: 294.37
SARS-CoV-2 3CLpro-IN-16 (Compound 3a) is a covalent SARS-CoV-2 3CLpro inhibitor (IC50s: 2.124 μM). SARS-CoV-2 3CLpro-IN
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.